ABVC Secures $70K Payment for Revolutionary Eye Treatment Vitargus

ABVC BioPharma, Inc. (NASDAQ: ABVC) has received a significant US$70,000 licensing payment from its strategic partner ForSeeCon Eye Corporation, marking another milestone in their global licensing agreement for Vitargus®, the world's first biodegradable vitreous substitute. This latest payment brings ForSeeCon's cumulative payments to US$566,000 under an agreement that carries a potential total value of up to US$93.5 million, including equity consideration, cash payments, and future royalties. The partnership represents a major advancement in ophthalmic innovation, with Vitargus® designed to revolutionize retinal surgery by eliminating the need for face-down positioning during recovery—a breakthrough that could significantly improve patient outcomes and comfort.

The financial impact extends beyond this single partnership, as ABVC has secured US$1,345,950 in licensing revenues across all current partnerships since the start of fiscal 2025. These revenues come with minimal incremental costs since development expenses were largely incurred in prior years, resulting in high-margin revenues that directly enhance ABVC's financial position. Management, including Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that these funds enable strategic reinvestment into the company's Good Manufacturing Practice (GMP) pharmaceutical facility in Hsinchu, Taiwan. This facility is critical for preparing GMP-compliant production of Vitargus®, moving the innovative product from development toward scalable, regulatory-compliant manufacturing necessary for future commercialization.

The market potential for Vitargus® is substantial, with independent market research estimating the global vitreous substitute market at US$2.5 billion in 2024, projected to grow to US$4.1 billion by 2033. ABVC's licensing framework with multiple partners, including AiBtl and OncoX, positions the company to capture both near-term liquidity and long-term growth opportunities in CNS, oncology, and ophthalmology. With more than US$12 million in future receivables potential, ABVC remains well-positioned to advance its pipeline of six drugs and one medical device while leveraging technology from prestigious research institutions including Stanford University and University of California at San Francisco.